A US-listed medical-devices maker of less-invasive cardiovascular and MedSurg products, with R&D and engineering operations in India
bostonscientific.comLegal name
Boston Scientific Corporation
CEO
Michael F. Mahoney, Chairman and CEO
CFO
Jonathan R. Monson, Chief Financial Officer
Founded
1979
Employees
About 59,000 (2025)
Industry
Medical devices
Revenue (FY25)
$20.074 billion net salesMarket Cap
About $64.2 billion (July 2026)Listed on
NYSE: BSX
Headquarters
Marlborough, Massachusetts, USA
Boston Scientific Corporation is a US medical-devices company founded in 1979 and headquartered in Marlborough, Massachusetts. It develops and sells less-invasive medical devices used across interventional specialties, organized into two reporting segments: Cardiovascular and MedSurg. The company trades on the New York Stock Exchange under the ticker BSX and is a component of the S&P 500.
For full-year 2025, Boston Scientific reported net sales of $20.074 billion. The company employs about 59,000 people as of 2025 and is led by Michael F. Mahoney, who serves as both Chairman and Chief Executive Officer. Jonathan R. Monson is Executive Vice President and Chief Financial Officer. As of July 2026 its market capitalization was roughly $64.2 billion.
Boston Scientific has an India presence through research, technology, and engineering operations. Its first Indian R&D center opened in Gurugram (Gurgaon), Haryana, and it later added a facility in Pune, Maharashtra. Global regional headquarters sit in Marlborough for corporate, Voisins-le-Bretonneux in France for Europe, Singapore for Asia Pacific, and Weston, Florida for Latin America.
Chairman and Chief Executive Officer
Executive Vice President and Chief Financial Officer
Executive Vice President and Group President, Cardiovascular
Executive Vice President and Group President, MedSurg and Asia Pacific
Interview experience
Positive, 7 out of 10
Interview difficulty
Medium, 4 out of 10
Interview process length
About a week or less
Browse question banks by role, round and company, with answers and examples.
Average base pay
$82,684/yr
438 Salaries submitted
Average base pay
$88,283/yr
364 Salaries submitted
Average base pay
$83,362/yr
208 Salaries submitted
Average base pay
$119,359/yr
152 Salaries submitted
Average base pay
$142,084/yr
116 Salaries submitted
Average base pay
$118,815/yr
83 Salaries submitted
Compare pay by role and see where you stand before you negotiate.
Pune, Maharashtra, India • Full-time
Gurgaon, Haryana, India • Contract (Off Roll)
Gurgaon, Haryana, India • Full-time
New Delhi, Delhi, India • Full-time
New Delhi, Delhi, India • Full-time
Greater Kolkata Area, India • Full-time
Free guides to AI video screens, coding tests and how scoring works.
May 18, 2026
Boston Scientific makes strategic investment in MiRus LLC
The deal includes an exclusive option to acquire a novel balloon-expandable transcatheter aortic valve built with a proprietary rhenium alloy. It extends the company's structural heart pipeline.
#investment #structuralheart #TAVR
View postMay 18, 2026
Boston Scientific enters $2 billion accelerated share repurchase agreement
The agreement forms part of the company's previously announced $5 billion share repurchase authorization. It signals confidence in cash generation and capital returns.
#buyback #capitalreturn #BSX
View postApril 26, 2026
New data at Heart Rhythm 2026 highlights FARAPULSE and WATCHMAN
Positive late-breaking clinical data for the FARAPULSE Pulsed Field Ablation system and WATCHMAN LAAC devices reinforced the safety and effectiveness of the therapies. The results were presented at the Heart Rhythm 2026 meeting.
#clinicaldata #electrophysiology #FARAPULSE
View postApril 22, 2026
Boston Scientific announces first quarter 2026 results
The company reported Q1 2026 revenue of about $5.20 billion, up 11.6% year over year, with adjusted EPS of $0.80. CEO Mike Mahoney credited the category leadership strategy for solid quarterly delivery.
#earnings #Q12026 #medtech
View postJanuary 15, 2026
Boston Scientific agrees to acquire Penumbra for about $14.5 billion
Boston Scientific announced a definitive agreement to acquire Penumbra in a cash and stock deal valuing it at $374 per share, an enterprise value of roughly $14.5 billion. The move expands its cardiovascular portfolio into mechanical thrombectomy and neurovascular markets.
#acquisition #cardiovascular #BSX
View postBoston Scientific develops and sells less-invasive medical devices across interventional specialties, organized into two segments: Cardiovascular and MedSurg.
Last updated:
